Sanofi Pasteur SA

Type: Company
Name: Sanofi Pasteur SA
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Sanofi Pasteur Supports 4th ASEAN Dengue Day

Sanofi Pasteur, the vaccines division of Sanofi supported the 4th annual ASEAN Dengue Day held on the 15 th of June 2014 in cooperation with ASEAN health stakeholders. Sanofi Pasteur is working with government, academic and medical stakeholders to hold ... [Published Medical Grapevine - 6 hours ago]
First reported 10 hours ago - Updated 10 hours ago - 1 reports

SANOFI : CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine

By a News Reporter-Staff News Editor at Biotech Week -- CureVac, a German clinical-stage biopharmaceutical company, announced the execution of an exclusive license agreement with Sanofi Pasteur S.A. , the vaccines division of Sanofi (EURONEXT: SAN and ... [Published 4 Traders - 10 hours ago]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine

Triggered by ongoing and very successful multi-year collaboration June 1, 2014CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive license agreement with Sanofi Pasteur S.A., the vaccines division ... [Published Terrapinn - Jul 07 2014]
First reported Jul 05 2014 - Updated Jul 06 2014 - 2 reports

Health Canada still concerned about Quebec flu vaccine plant

TORONTO – Health Canada has advised pharmaceutical giant GSK it wants to see an action plan for fixing problems at the country’s only flu vaccine production facility.GSK was given 30 days in which to lay out a proposal and timeline for resolving the problems ... [Published Global News Canada - Jul 05 2014]
First reported Jul 06 2014 - Updated Jul 06 2014 - 1 reports

Jianxin Zhang, Sanofi Pasteur, to Speak at Protein-Protein Interaction, Oct. 23-24, 2014 in Boston

Boston, MA, July 06, 2014 --( PR.com )-- Jianxin Zhang, Deputy Director of Protein Characterization at Sanofi Pasteur, will give a presentation on, “Antigen-Antibody Interaction Analyzed by Hydrogen-Deuterium Exchange Mass Spectrometry” at the 2nd Protein-Protein ... [Published PR.com Press Releases - Jul 06 2014]
First reported Jul 05 2014 - Updated Jul 05 2014 - 1 reports

Dodging the dengue fever bullet

| 03:42 PMSpecial ReportPhuket consistently has among the highest number of dengue sufferers in the country, and the disease has killed one 24-year-old woman in Patong and hospitalized hundreds of others on the island already this year.Yet hope is on ... [Published Phuket Gazette - Jul 05 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

Japan marketing approval for Canaglu; Vaccine license for Daiichi Sankyo

Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) has received approval to manufacture and market the SGLT2 inhibitor, Canaglu (canagliflozin hydrate) Japan, for the treatment of patients with type 2 diabetes mellitus.Mitsubishi Tanabe, which discovered ... [Published Pharma Letter - Jul 04 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

Jianxin Zhang, Sanofi Pasteur, to Speak at Protein-Protein Interaction, Oct. 23-24, 2014 in Boston

- Jianxin Zhang, Deputy Director of Protein Characterization at Sanofi Pasteur, will give a presentation on, “Antigen-Antibody Interaction Analyzed by Hydrogen-Deuterium Exchange Mass Spectrometry” at the 2nd Protein-Protein Interaction Conference to ... [Published PR inside - Jul 04 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Tdap Vaccines Showed Waning Efficacy During 2012 Pertussis Outbreak

During a 2012 outbreak of pertussis in Wisconsin, inoculation of adolescents with Tdap vaccinations showed dwindling immunity with time, according to recent findings.Although the Boostrix (GlaxoSmithKline) Tdap vaccine demonstrated greater efficacy than ... [Published RT Magazine - Jul 03 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Vaccines Cost an Absolute God-Almighty Fortune

While everyone was busy with Facebook fights over the safety of childhood vaccines (GET IT TOGETHER, AMERICA), they've become vastly more expensive. Costs have leapt so high many doctors are struggling to offer them, leaving some parents scrambling for ... [Published Jezebel - Jul 03 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 3 reports

Sanofi, CureVac extend vax partnership with new $205M-plus mRNA pact

Sanofi Pasteur and Germany's CureVac first joined up in 2011 with a licensing option agreement for a slew of pathogens. Now, they're beefing up their partnership with another licensing deal, this one giving the French company rights to a new mRNA-based ... [Published FierceVaccines - Jul 03 2014]
First reported Jul 01 2014 - Updated Jul 02 2014 - 8 reports

CureVac, Sanofi Pasteur ink license agreement

TUBINGEN, Germany—Clinical-stage biopharmaceutical company CureVac has announced the establishment of an exclusive license agreement with , the vaccines division of Sanofi, for the development and commercialization of an mRNA-based vaccine against an ... [Published Drug Discovery News - Jul 02 2014]

Quotes

...patients' needs is furthered by our collaboration with CureVac," comments Nicolas Burdin , Head of Discovery Research at Sanofi Pasteur in France . "Accessing CureVac's innovative mRNA technology may allow Sanofi Pasteur to exploit a platform that can be more broadly applicable across indications to develop vaccines, as the RNActive(®) technology is expected to complement conventional technologies."
Albany, NY -- ( SBWIRE ) -- 07/09/2014 -- According to a new report published by Transparency Market Research "Meningococcal Vaccines Market (Polysaccharide, Conjugate, and Combination Vaccines, along with Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3...
"We have 30 days to review and respond to the findings noted in their report and we are committed to doing so by August 4, 2014" said the email from Michelle Smolenaars Hunter, communications manager for GSK Canada
...But as former head of the C D C 's immunization Dr. Alan Hinman put it to the Times : "A more difficult question is, after the researchresearch and development costs are recouped, why don't prices come down?" (I'm gonna guess $$$$$$$$.)

More Content

All (167) | News (133) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
Sanofi Pasteur Supports 4th ASEAN Dengue Day [Published Medical Grapevine - 6 hours ago]
SANOFI : CureVac Signs an Exclusive License Agr... [Published 4 Traders - 10 hours ago]
Meningococcal Vaccines Market - Global Industry... [Published SBWire - 14 hours ago]
Fostering Innovations to Meet the Global Gap of... [Published PRWeb - Jul 08 2014]
Measurement of Neutralizing Serum Antibodies of... [Published Plosone.org - Jul 07 2014]
CureVac Signs an Exclusive License Agreement wi... [Published Terrapinn - Jul 07 2014]
Jianxin Zhang, Sanofi Pasteur, to Speak at Prot... [Published PR.com Press Releases - Jul 06 2014]
Health Canada still concerned about Quebec flu ... [Published Global News Canada - Jul 05 2014]
Health Canada inspection raises concerns about ... [Published 1057 EZRrock - Jul 05 2014]
Dodging the dengue fever bullet [Published Phuket Gazette - Jul 05 2014]
Japan marketing approval for Canaglu; Vaccine l... [Published Pharma Letter - Jul 04 2014]
Jianxin Zhang, Sanofi Pasteur, to Speak at Prot... [Published PR inside - Jul 04 2014]
Tdap Vaccines Showed Waning Efficacy During 201... [Published RT Magazine - Jul 03 2014]
Vaccines Cost an Absolute God-Almighty Fortune [Published Jezebel - Jul 03 2014]
Sanofi, CureVac extend vax partnership with new... [Published FierceVaccines - Jul 03 2014]
CureVac signs agreement with Sanofi to develop ... [Published BioPrepWatch - Jul 03 2014]
CureVac and Sanofi Pasteur to develop an mRNA-b... [Published Manufacturing Chemist - Jul 03 2014]
Sanofi Pasteur MSD: Who’s running the show [Published BioPortfolio - Jul 02 2014]
CureVac, Sanofi Pasteur ink license deal for mR... [Published Pharmaceutical Business Review - Jul 02 2014]
CureVac, Sanofi Pasteur ink license agreement [Published Drug Discovery News - Jul 02 2014]
CureVac, Sanofi Paster in 150m-euro-plus vaccin... [Published Pharma Times - Jul 02 2014]
BUENA VISTA COUNTY CLAIMS LISTING [Published Storm Lake Pilot Tribune - Jul 01 2014]
CureVac in deal with Sanofi Pasteur for mRNA-ba... [Published Pharma Letter - Jul 01 2014]
CureVac Licenses RNActive Vaccine Rights to San... [Published Genetic Engineering News - Jul 01 2014]
CureVac Signs an Exclusive License Agreement wi... [Published Wall Street Select - Jul 01 2014]
CureVac Signs an Exclusive License Agreement wi... [Published ADVFN India - Jul 01 2014]
CureVac Signs an Exclusive License Agreement wi... [Published Tamar Securities - Jul 01 2014]
CureVac Signs an Exclusive License Agreement wi... [Published PR Newswire: General Business - Jul 01 2014]
Farshad Guirakhoo Joins Vaxess Technologies As ... [Published Terrapinn - Jun 30 2014]
On Canada Day, Let's Celebrate Maternal Health [Published Huffington Post Canada - Jun 30 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Jianxin Zhang, Sanofi Pasteur, to Speak at Prot... [Published PR.com Press Releases - Jul 06 2014]
Boston, MA, July 06, 2014 --( PR.com )-- Jianxin Zhang, Deputy Director of Protein Characterization at Sanofi Pasteur, will give a presentation on, “Antigen-Antibody Interaction Analyzed by Hydrogen-Deuterium Exchange Mass Spectrometry” at the 2nd Protein-Protein ...
CureVac Signs an Exclusive License Agreement wi... [Published PR Newswire: General Business - Jul 01 2014]
TUBINGEN, Germany, July 1, 2014 /PRNewswire/ -- CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive license agreement with Sanofi Pasteur S.A., the vaccines division of Sanofi (EURONEXT: SAN and NYSE: ...
Turning the Tide on STEM Education [Published I Am Biotech - Jun 24 2014]
According to the US Department of Education, only 16 percent of American high school seniors are proficient in mathematics and interested in a career in a Science, Technology, Engineering or Math (STEM) field. Even among students who do major in a STEM ...
Chih-Jen (CJ) Wei, Sanofi Pasteur to Present at... [Published PR.com Press Releases - Jun 19 2014]
Boston, MA, June 19, 2014 --( PR.com )-- Chih-Jen (CJ) Wei, Director at Sanofi Pasteur will give a presentation on, “A Self-Assembling Influenza Nanoparticle Vaccine Elicits Broad and Potent Neutralizing Antibodies” at the 12th Vaccines Research & Development: ...
Buffy the Vampire Slayer: let's slay whooping c... [Published Boing Boing - Jun 17 2014]
Not all celebrities oppose vaccines and the good sense of science. At CNN.com , actress Sarah Michelle Gellar has an op-ed as a spokesperson for an anti-pertussis awareness campaign organized by Sanofi Pasteur and The March of Dimes. Read the rest ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Sanofi Pasteur Allies with SK Chemical Co. of S... [Published Sanofi.com - Last press releases - Mar 19 2014]
“India’s vast polio achievement is a call for a... [Published Sanofi.com - Last press releases - Feb 11 2014]
PATH Malaria Vaccine Initiative Names New Director [Published PR Newswire - Oct 22 2013]
Flu Vaccination Coverage on the Rise; Health Of... [Published PR Newswire - Sep 26 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.